Clinical Trial Update: Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing BEBT-908 plus Rituximab-based standard of care versus standard of care in relapsed/refractory diffuse large B-cell lymphoma; en…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• BEBT-908 (BEBT-908)
• Rituximab (rituximab)

Snippet

Sponsor: BeBetter Med Inc | Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Status: RECRUITING